US 11642390
Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody
granted A61KA61K38/00A61K38/08
Quick answer
US patent 11642390 (Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K38/00, A61K38/08, A61K38/10, A61K38/22